{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Okamoto R"],"funding":["NCI NIH HHS"],"pagination":["2464-73"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3288172"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["130(10)"],"pubmed_abstract":["19-nor-14-epi-23-yne-1,25(OH)(2) D(3)  (inecalcitol) is a unique vitamin D(3)  analog. We evaluated the activity of inecalcitol in a human prostate cancer model system. The analog was 11-fold more potent than 1,25(OH)(2) D(3)  in causing 50% clonal growth inhibition of androgen-sensitive human prostate cancer LNCaP cells. Inecalcitol, more than 1,25(OH)(2) D(3) , reduced in a dose-dependent manner the expression levels of the transcription factor ETS variant 1 and the serine/threonine protein kinase Pim-1, both of which are upregulated in prostate cancer. Remarkably, dose challenge experiments revealed that inecalcitol maximal tolerated dose (MTD) by intraperitoneal (i.p.) administration was 30 μg/mouse (1,300 μg/kg) three times per week, while we previously found that the MTD of 1,25(OH)("],"journal":["International journal of cancer"],"pubmed_title":["Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells."],"pmcid":["PMC3288172"],"funding_grant_id":["U54 CA143930","R01 CA026038","R01 CA026038-32","U54 CA143930-01"],"pubmed_authors":["Shen M","Delansorne R","Wakimoto N","Said JW","Doan NB","Ho QH","Koeffler HP","Okamoto R","Akagi T"],"additional_accession":[]},"is_claimable":false,"name":"Inecalcitol, an analog of 1α,25(OH)(2) D(3) , induces growth arrest of androgen-dependent prostate cancer cells.","description":"19-nor-14-epi-23-yne-1,25(OH)(2) D(3)  (inecalcitol) is a unique vitamin D(3)  analog. We evaluated the activity of inecalcitol in a human prostate cancer model system. The analog was 11-fold more potent than 1,25(OH)(2) D(3)  in causing 50% clonal growth inhibition of androgen-sensitive human prostate cancer LNCaP cells. Inecalcitol, more than 1,25(OH)(2) D(3) , reduced in a dose-dependent manner the expression levels of the transcription factor ETS variant 1 and the serine/threonine protein kinase Pim-1, both of which are upregulated in prostate cancer. Remarkably, dose challenge experiments revealed that inecalcitol maximal tolerated dose (MTD) by intraperitoneal (i.p.) administration was 30 μg/mouse (1,300 μg/kg) three times per week, while we previously found that the MTD of 1,25(OH)(","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 May","modification":"2025-06-27T03:05:06.627Z","creation":"2025-06-27T03:05:06.627Z"},"accession":"S-EPMC3288172","cross_references":{"pubmed":["21732345"],"doi":["10.1002/ijc.26279"]}}